Emory Expands LIBERTY Use, But Microbot's Commercialization Risk Remains High

What happened

Microbot Medical's LIBERTY endovascular robotic system, first adopted by Emory University Hospital in late 2025, has seen expanded clinical use at the same institution. On March 26, 2026, Emory Healthcare announced successful completion of robotic peripheral endovascular procedures, including the world's first robotic Prostatic Artery Embolization for benign prostatic hyperplasia and Y-90 radioembolization mapping for liver cancer. This development demonstrates LIBERTY's capability across multiple case types and reinforces its clinical validation as a single-use robotic platform. However, the announcement does not disclose any new hospital adoptions or provide metrics on procedure volumes or revenue, leaving the commercialization thesis unchanged. Microbot remains in the Limited Market Release phase, with the critical Full Market Release scheduled for Q2 2026, and investors are still awaiting evidence of broader market penetration.

Implication

The successful procedures at Emory confirm that LIBERTY is operationally effective and can handle diverse endovascular cases, which is positive for technology credibility. Nonetheless, this single-site success does not translate into commercial scalability, as hospital adoption decisions depend on broader economic and operational factors. Without disclosure of additional paying hospitals or disposable usage data, the risk of commercialization failure remains high, per the DeepValue report's thesis breakers. Investors should continue to monitor for announcements of new installations and revenue metrics, as these are necessary to shift the investment rating from WAIT to a more favorable stance. Until such evidence emerges, the stock's valuation at ~$2.10 reflects speculative optimism rather than proven business traction.

Thesis delta

The investment thesis does not materially change with this news. The DeepValue report's WAIT rating and key milestones—such as achieving ≥10 paying LIBERTY sites with documented recurring usage by YE 2026—remain unaltered, as this update only reinforces existing clinical validation without demonstrating broader market adoption. While it slightly supports the bull case's clinician enthusiasm, the probability of that scenario remains low until multi-hospital traction is proven.